Patient Square Capital LP Has $3.98 Million Position in Pharvaris (NASDAQ:PHVS)

Patient Square Capital LP trimmed its position in shares of Pharvaris (NASDAQ:PHVS - Free Report) by 14.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 207,603 shares of the company's stock after selling 34,738 shares during the period. Pharvaris makes up 1.5% of Patient Square Capital LP's portfolio, making the stock its 12th biggest position. Patient Square Capital LP owned 0.40% of Pharvaris worth $3,980,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Octagon Capital Advisors LP boosted its stake in Pharvaris by 25.4% during the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock valued at $14,914,000 after acquiring an additional 157,530 shares during the last quarter. Deutsche Bank AG lifted its position in Pharvaris by 13.0% in the 4th quarter. Deutsche Bank AG now owns 18,168 shares of the company's stock valued at $348,000 after purchasing an additional 2,087 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Pharvaris during the 4th quarter worth about $64,000. Bank of America Corp DE raised its position in shares of Pharvaris by 205,286.7% during the 4th quarter. Bank of America Corp DE now owns 30,808 shares of the company's stock worth $591,000 after buying an additional 30,793 shares in the last quarter. Finally, Northern Trust Corp grew its stake in shares of Pharvaris by 483.9% in the 4th quarter. Northern Trust Corp now owns 91,932 shares of the company's stock worth $1,762,000 after purchasing an additional 76,188 shares during the last quarter.

Pharvaris Trading Down 0.1%

NASDAQ:PHVS traded down $0.02 during trading hours on Monday, hitting $16.55. 21,794 shares of the company traded hands, compared to its average volume of 74,096. Pharvaris has a twelve month low of $11.51 and a twelve month high of $25.50. The stock has a market capitalization of $865.14 million, a price-to-earnings ratio of -5.91 and a beta of -2.85. The firm has a 50-day moving average of $15.38 and a 200 day moving average of $17.58.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.09). Equities research analysts predict that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on PHVS. Cantor Fitzgerald lowered their price objective on shares of Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 14th. JMP Securities lifted their target price on shares of Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a research report on Friday, January 31st.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.